Section of Medical Oncology and hematology, University of Manitoba, Winnipeg, Manitoba, Canada.
Research Institute of Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
JAMA Netw Open. 2020 Sep 1;3(9):e2018179. doi: 10.1001/jamanetworkopen.2020.18179.
Breast cancer comprises a highly heterogeneous group of diseases. Many breast cancers, particularly the more lethal ones, may not satisfy the assumptions about biology and natural history of breast cancer necessary for screening mammography to be effective.
To compare tumor characteristics of breast cancers diagnosed within 2 years of a normal screening mammogram (interval breast cancer [IBC]) with those of screen-detected breast cancers (SBC) and to compare breast cancer-specific mortality of IBC with SBC.
DESIGN, SETTING, AND PARTICIPANTS: In this registry-based cohort study, we collected data about relevant tumor- and patient-related variables on women diagnosed with breast cancer between January 2004 and June 2010 who participated in the population-based screening program in Manitoba, Canada, and those diagnosed with breast cancer outside the screening program in the province. We performed multinomial logistic regression analysis to assess tumor and patient characteristics associated with a diagnosis of IBC compared with SBC. Competing risk analysis was performed to examine risk of death by cancer detection method.
Breast cancer diagnosis.
Differences in tumor characteristics and breast cancer-specific mortality.
A total of 69 025 women aged 50 to 64 years had 212 screening mammograms during the study period. There were 1687 breast cancer diagnoses (705 SBC, 206 IBC, 275 were noncompliant, and 501 were detected outside the screening program), and 225 deaths (170 breast cancer-specific deaths). Interval cancers were more likely than SBC to be of high grade and estrogen receptor negative (odds ratio [OR], 6.33; 95% CI, 3.73-10.75; P < .001; and OR, 2.88; 95% CI, 2.01-4.13; P < .001, respectively). After a median follow-up of 7 years, breast cancer-specific mortality was significantly higher for IBC compared with SBC cancers (hazard ratio [HR] 3.55; 95% CI, 2.01-6.28; P < .001), for a sojorn time of 2 years. Non-breast cancer mortality was similar between IBC and SBC (HR, 1.33; 95% CI, 0.43-4.15).
In this cohort study, interval cancers were highly prevalent in women participating in population screening, represented a worse biology, and had a hazard for breast cancer death more than 3-fold that for SBC. Strategies beyond current mammographic screening practices are needed to reduce incidence, improve detection, and reduce deaths from these potentially lethal breast cancers.
乳腺癌包含一组高度异质的疾病。许多乳腺癌,尤其是更致命的乳腺癌,可能不符合筛查乳房 X 光检查有效性所需的生物学和自然史假设。
比较在正常筛查乳房 X 光检查(间隔性乳腺癌[IBC])后 2 年内诊断出的乳腺癌与筛查发现的乳腺癌(SBC)之间的肿瘤特征,并比较 IBC 与 SBC 的乳腺癌特异性死亡率。
设计、地点和参与者:在这项基于注册的队列研究中,我们收集了 2004 年 1 月至 2010 年 6 月期间在加拿大马尼托巴省参加基于人群的筛查计划时诊断出的患有乳腺癌的女性和在该省筛查计划之外诊断出的患有乳腺癌的女性的相关肿瘤和患者相关变量的数据。我们进行了多项逻辑回归分析,以评估与 SBC 相比,与 IBC 诊断相关的肿瘤和患者特征。竞争风险分析用于检查通过癌症检测方法的死亡风险。
乳腺癌诊断。
肿瘤特征和乳腺癌特异性死亡率的差异。
共有 69525 名 50 至 64 岁的女性在研究期间进行了 212 次筛查乳房 X 光检查。有 1687 例乳腺癌诊断(705 例 SBC、206 例 IBC、275 例不符合规定、501 例在筛查计划之外发现)和 225 例死亡(170 例乳腺癌特异性死亡)。间隔性癌症比 SBC 更有可能为高级别和雌激素受体阴性(比值比[OR],6.33;95%置信区间[CI],3.73-10.75;P<0.001;OR,2.88;95%CI,2.01-4.13;P<0.001)。中位随访 7 年后,IBC 的乳腺癌特异性死亡率明显高于 SBC 癌症(危险比[HR],3.55;95%CI,2.01-6.28;P<0.001),间隔为 2 年。IBC 和 SBC 的非乳腺癌死亡率相似(HR,1.33;95%CI,0.43-4.15)。
在这项队列研究中,间隔性癌症在参加人群筛查的女性中发病率很高,代表了更差的生物学特征,并且乳腺癌死亡的风险是 SBC 的 3 倍以上。需要超越当前乳房 X 光筛查实践的策略来降低这些潜在致命乳腺癌的发病率、提高检出率并降低死亡率。